Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.35 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15227998 | 0.87 | IP6K1 (0.36) | IP6K1CALCRLRAMP1ALDH1A1L3MBTL1 | |
| SCHEMBL7031017 | 0.81 | CALCRL (0.43) | IP6K1CSNK2A1CALCRLRAMP1ALDH1A1 | |
| SCHEMBL261335 | 0.78 | CA9 (0.32) | CALCRL | |
| SCHEMBL29416274 | 0.77 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL22796626 | 0.77 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL15236128 | 0.77 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL1814470 | 0.77 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL29517886 | 0.77 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL31084970 | 0.77 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL29517961 | 0.77 | CALCRL (0.51) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2849568-B1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3430906-A1 | CRYSTALLINE FORMS OF CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9850246-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850246-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2846801-B1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2637656-B1 | N-Piperidinone-indane carboxamides as CGRP receptor antagonists | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9499541-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499541-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-8883807-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883807-B2 | Piperidinone carboxamide indane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130261138-A1 | FUSED HETEROCYCLIC INDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| US-20130261138-A1 | FUSED HETEROCYCLIC INDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-09-05 | — | — | US | disclosed |
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-09-05 | — | — | US | disclosed |
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-09-05 | — | — | US | disclosed |
| WO-2012087777-A1 | FUSED HETEROCYCLIC INDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012064911-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231358-A1 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | IP6K1 892/4885CSNK2A1 1759/4885CALCRL 1/4885 |
| US-20130261138-A1 | FUSED HETEROCYCLIC INDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, CNR2 | IP6K1 1507/4885CSNK2A1 2034/4885CALCRL 2/4885 |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, VIPR1 | IP6K1 733/4885CSNK2A1 2313/4885CALCRL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.